Board Member
Verizon Communications Inc (VZ)Equibles does not estimate personal net worth.
Get an email with a short summary when Merck & Co., Inc. publishes a filing, an earnings call transcript or a press release.
Get MRK alertsCaroline Litchfield is recorded as CFO at Merck & Co., Inc. (MRK) and Board Member at Verizon Communications Inc (VZ) since May 21, 2026. The proxy statement of Merck & Co., Inc. reports total compensation of $7,514,085 for Caroline Litchfield in fiscal 2025, including a base salary of $1,173,214. Disclosed compensation is on record for 7 fiscal years. Caroline Litchfield has spoken on 20 earnings calls and 2 other investor events across 1 company, most recently for Merck & Co., Inc. on September 9, 2026. Merck & Co., Inc. is classified in the Drug Manufacturers - General industry within the Healthcare sector. Verizon Communications Inc is classified in the Telecom Services industry within the Communication Services sector. Other leadership on record at Merck & Co., Inc. includes Robert M. Davis (CEO, Chairman and Board Member), Jennifer Zachary (General Counsel), Dalton E. Smart III (Chief Accounting Officer) and 7 others.
“So thank you all for being here today and thank you for your interest in and support of Merck. Since we were here a year ago, we've made tremendous progress and that progress is all anchored towards driving our long-term growth ambition.”
“So thank you all for being here today and thank you for your interest in and support of Merck. Since we were here a year ago, we've made tremendous progress and that progress is all anchored towards driving our long-term growth ambition.”
“We delivered growth in the quarter, led by continued strength in oncology and animal health, along with increasing contributions from our diverse and compelling new products across an array of therapeutic areas.”
“As Rob noted, we delivered growth in the quarter driven by continued strength in oncology and animal health, as well as increasing contributions from our many compelling product launches.”
“As Rob noted, in 2025, we made meaningful progress in benefiting patients and customers around the world with our portfolio of innovative medicines and vaccines.”
2026-05-21–present
Drug Manufacturers - General · Healthcare
CFO
Telecom Services · Communication Services
Board Member
2026-05-21–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Merck & Co., Inc. (MRK) | Executive Vice President and Chief Financial Officer | $1,173,214 | $7,514,085 |
| 2024 | Merck & Co., Inc. (MRK) | Executive Vice President and Chief Financial Officer | $1,166,044 | $7,507,778 |
| 2023 | Merck & Co., Inc. (MRK) | Executive Vice President and Chief Financial Officer | $1,093,063 | $8,300,385 |
| 2022 | Merck & Co., Inc. (MRK) | Executive Vice President and Chief Financial Officer | $959,959 | $5,922,657 |
| 2021 | Merck & Co., Inc. (MRK) | Executive Vice President and Chief Financial Officer | $805,060 | $4,596,630 |
| 2020 | Merck & Co., Inc. (MRK) | Executive Vice President and Chief Financial Officer | — | — |
| 2019 | Merck & Co., Inc. (MRK) | Executive Vice President and Chief Financial Officer | — | — |
